TW319769B - - Google Patents

Download PDF

Info

Publication number
TW319769B
TW319769B TW084106000A TW84106000A TW319769B TW 319769 B TW319769 B TW 319769B TW 084106000 A TW084106000 A TW 084106000A TW 84106000 A TW84106000 A TW 84106000A TW 319769 B TW319769 B TW 319769B
Authority
TW
Taiwan
Prior art keywords
group
item
carboxylic acid
salt
patent application
Prior art date
Application number
TW084106000A
Other languages
English (en)
Chinese (zh)
Original Assignee
Dai Nippon Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dai Nippon Seiyaku Kk filed Critical Dai Nippon Seiyaku Kk
Application granted granted Critical
Publication of TW319769B publication Critical patent/TW319769B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW084106000A 1994-06-14 1995-06-13 TW319769B (instruction)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13

Publications (1)

Publication Number Publication Date
TW319769B true TW319769B (instruction) 1997-11-11

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084106000A TW319769B (instruction) 1994-06-14 1995-06-13

Country Status (27)

Country Link
US (1) US5817669A (instruction)
EP (1) EP0787726B1 (instruction)
JP (1) JP3391796B2 (instruction)
KR (1) KR100350921B1 (instruction)
CN (1) CN1053668C (instruction)
AT (1) ATE209645T1 (instruction)
AU (1) AU679859B2 (instruction)
BR (1) BR9508037A (instruction)
CA (1) CA2192824C (instruction)
CZ (1) CZ292631B6 (instruction)
DE (1) DE69524251T2 (instruction)
DK (1) DK0787726T3 (instruction)
ES (1) ES2163512T3 (instruction)
FI (1) FI112485B (instruction)
HK (1) HK1000495A1 (instruction)
HU (1) HU220072B (instruction)
MX (1) MX9606331A (instruction)
NO (1) NO307255B1 (instruction)
NZ (1) NZ287139A (instruction)
PL (1) PL181867B1 (instruction)
PT (1) PT787726E (instruction)
RO (1) RO117793B1 (instruction)
RU (1) RU2151770C1 (instruction)
SI (1) SI0787726T1 (instruction)
SK (1) SK281341B6 (instruction)
TW (1) TW319769B (instruction)
WO (1) WO1995034559A1 (instruction)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504808A (ja) 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
JP4639149B2 (ja) * 2003-09-10 2011-02-23 杏林製薬株式会社 ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
ZA200607248B (en) * 2004-03-15 2009-02-25 Sunesis Pharmaceutical Inc SNS-595 and methods of using the same
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
US7268231B2 (en) * 2004-10-14 2007-09-11 Hoffmann-La Roche Inc. 1,5-Naphthyridine azolinone
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
KR20140057409A (ko) * 2005-09-02 2014-05-12 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP3025712A1 (en) * 2006-08-02 2016-06-01 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
CN103720701A (zh) * 2007-10-22 2014-04-16 逊尼希思制药公司 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
AU2008335772B2 (en) * 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
NZ593763A (en) 2008-12-31 2013-11-29 Sunesis Pharmaceuticals Inc Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG10201400258SA (en) 2009-02-27 2014-05-29 Sunesis Pharmaceuticals Inc Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
PL2712358T3 (pl) * 2011-05-13 2017-05-31 Array Biopharma, Inc. Związki mocznika pirolidynowego, tiomocznika pirolidynowego oraz guanidyny pirolidynowej jako inhibitory kinazy trka
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
WO2018174266A1 (ja) * 2017-03-24 2018-09-27 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
IE60420B1 (en) * 1985-06-13 1994-07-13 Schering Corp Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
JP3391796B2 (ja) 2003-03-31
ATE209645T1 (de) 2001-12-15
SI0787726T1 (en) 2002-04-30
SK281341B6 (sk) 2001-02-12
CZ364396A3 (en) 1997-06-11
CA2192824C (en) 2006-11-07
NO307255B1 (no) 2000-03-06
NO965305L (no) 1997-02-04
FI965020A0 (fi) 1996-12-13
DK0787726T3 (da) 2002-02-11
HUT75777A (en) 1997-05-28
RO117793B1 (ro) 2002-07-30
EP0787726B1 (en) 2001-11-28
CZ292631B6 (cs) 2003-11-12
US5817669A (en) 1998-10-06
AU679859B2 (en) 1997-07-10
KR100350921B1 (ko) 2002-11-18
DE69524251T2 (de) 2002-07-11
HU9603455D0 (en) 1997-02-28
PL317726A1 (en) 1997-04-28
FI965020A7 (fi) 1996-12-16
SK157496A3 (en) 1997-08-06
CN1158614A (zh) 1997-09-03
PT787726E (pt) 2002-04-29
CN1053668C (zh) 2000-06-21
NZ287139A (en) 1997-07-27
BR9508037A (pt) 1997-09-16
EP0787726A4 (instruction) 1997-08-06
ES2163512T3 (es) 2002-02-01
PL181867B1 (pl) 2001-09-28
EP0787726A1 (en) 1997-08-06
MX9606331A (es) 1997-03-29
CA2192824A1 (en) 1995-12-21
HK1000495A1 (en) 2002-07-19
WO1995034559A1 (fr) 1995-12-21
NO965305D0 (no) 1996-12-11
DE69524251D1 (de) 2002-01-10
HU220072B (hu) 2001-10-28
FI112485B (fi) 2003-12-15
RU2151770C1 (ru) 2000-06-27
AU2576795A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
TW319769B (instruction)
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
JP4323574B2 (ja) 抗腫瘍剤
WO2020156243A1 (zh) Shp2抑制剂及其应用
CN107849013A (zh) 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
WO2020216190A1 (zh) 一种喹唑啉化合物及其在医药上的应用
CN109803968A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
CN109715634A (zh) Menin-mll相互作用的稠合二环抑制剂
CN109803651A (zh) 免疫调节剂化合物
CN108707140A (zh) 蛋白酶c抑制剂
AU2014294866B2 (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
CN106573934B (zh) 瞬时受体电位a1离子通道的抑制
WO2023280237A1 (zh) 一种磷酸酶降解剂的合成和应用
CN101801950A (zh) 作为黑皮质素-4受体调质的取代的杂芳基哌啶衍生物
TW200813022A (en) Organic compounds
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
CN109641882A (zh) 作为nik抑制剂的杂芳族衍生物
WO2023143352A1 (zh) 一种含氮杂环化合物、其制备方法及应用
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
CN109689645A (zh) 作为nik抑制剂的氰基吲哚啉衍生物
TWI300066B (en) Pharmaceutically active compounds
TW202003487A (zh) 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法
TW201736367A (zh) 6,7,8,9-四氫-5H-吡啶并[2,3-d]氮呯多巴胺D3配體
CN107304211A (zh) 一种选择性fgfr4激酶抑制剂
TWI229079B (en) Tetrahydroquinoline derivatives, pharmaceutical composition comprising them and process for the preparation of the same

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent